Tarsus Share Discussion Threads

[peladon] 14/2/2007 08:15

Market slow to respond.

But it will eventuallly.

[saucepan] 14/2/2007 07:23

A nice RNS this morning "Chinese Partnership" (link in the thread header).

I wonder if this will be enough to get the shares motoring and into breakout mode. I suspect it might.

[ebslight] 19/1/2007 18:47

Volume building, any break above 261 should be interesting

[holgerl] 09/1/2007 00:09

chart looks very strong

[ian.g] 04/1/2007 10:43

Consolidation pullback seems to have been very short-lived, and a good solid trading statement this morning - but "meeting expectations" for the financial year may not be as good as some had hoped. Still watching: will consider buying back in if a suitable opportunity presents itself.

[holgerl] 03/1/2007 08:28

lookin good

[holgerl] 19/12/2006 08:01

baby looks ready to run

[holgerl] 18/12/2006 22:54

maybe time to get in again,looks ready for a breakout!

[ian.g] 14/12/2006 16:08

that'll teach me not to believe in my own targets!
best of luck to all holders...

[holgerl] 12/12/2006 19:59

Anyon have a target more than 623p?

[holmess] 11/12/2006 10:45

top banana

[miked500] 11/12/2006 10:20

one of the tips for the coming year in sharewatch.

[bonzo] 11/12/2006 08:33

Breakout resumed... got in following an FT tip earlier in the year and very happy!

[ian.g] 06/12/2006 12:00

Did look like a breakout, but then appeared to stall.
No volume yesterday or today, and looking back at the trades on the 4th they look to me very manipulative.
My target was 260, but I've sold out today for 240.
Still strongly believe this is a great company, but will watch for the price to (hopefully) drop back before buying in.
The support line for the current channel I'd say was around 210.
Of course I may just have been suckered and the price could head on up: I have to say I had no problem selling my little holding... still, I've done ok here for now, mustn't be greedy...
Good luck to all holders,
Ian

[holmess] 04/12/2006 15:51

Looking very much like a breakout today. Good stuff!

[ian.g] 20/11/2006 10:22

sp taking a little breather now - the air's thin up here ;-)
needs to stabilise a bit before the push up to 260.

[ian.g] 17/11/2006 15:21

holmess
nice to see you here - not bad so far :-)

[holmess] 17/11/2006 10:53

ian.g - going nicely!

[ian.g] 16/11/2006 17:53

oscar,
lol - judging from the share price increase during the day a few more have as well...

[ian.g] 16/11/2006 11:09

...and now we know the reason for the rise - another smaller conference organiser bought, as TRS continue to consolidate their position:
16 November 2006


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO
THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, REPUBLIC OF SOUTH AFRICA,
REPUBLIC OF IRELAND OR JAPAN


Tarsus Group plc

Acquisition of Medical Conferences International Inc. and Vendor Placing


Tarsus Group plc ("Tarsus" or "the Company") (LSE: TRS), the international media
group with interests in exhibitions, conferences, publishing and online media,
is pleased to announce that it has agreed to acquire 80% of the issued share
capital of Medical Conferences International Inc. ("MCII") (the "Acquisition")
from Dr. Robert Goldman MD, PhD, DO, FAASP, and Dr. Ronald Klatz MD, DO (the
"Vendors").

The total consideration for the Acquisition is US$46.0 million plus an amount
equal to the net assets of MCII on completion which is estimated to be US$3.0
million. US$36.0 million (approximately #19.1 million) of the consideration is
payable to the Vendors in cash on completion (the "initial consideration") and
up to a further US$10 million is payable as deferred consideration. The
deferred consideration is payable over up to five years subject to certain
performance criteria relating to the level of growth achieved by MCII over a 5
year period. The payment for MCII's net assets is payable in cash following
preparation of completion accounts.

The Company is also pleased to announce that KBC Peel Hunt Ltd ("KBC Peel Hunt")
has conditionally placed 5,304,107 new ordinary shares of 5p each in the
Company ("Ordinary Shares") by way of a vendor placing to raise approximately
#11.0 million to partially fund the initial consideration (the "Vendor
Placing"). The Vendor Placing has been fully underwritten by KBC Peel Hunt.
Further, the Company has today extended its existing bank facility with Royal
Bank of Scotland by #10 million, repayable over a 5 year period, to fund the
balance of the initial consideration.

In the year to 31 December 2005, MCII's unaudited turnover was US$3.9 million,
adjusted profits before tax was US$1.7 million and gross assets were US$1.9
million. The Vendors have warranted that adjusted pre-tax profits for the year
to 31 December 2006 will be not less than US$5.5 million.

Completion of the Acquisition is conditional, inter alia, on completion of the
Vendor Placing, which is expected to occur on 21 November 2006.


Information on MCII

MCII, founded in 2003 by Dr Goldman and Dr Klatz, owns and operates the three
leading medical sector exhibitions and conferences in the US anti-ageing market
which take place annually in Orlando (April), Chicago (July) and Las Vegas
(December). The upcoming event in December 2006 is expected to be attended by at
least 5,000 doctors and healthcare professionals, and for many of them will
contribute towards ongoing professional accreditation.


MCII has been expanding the brand internationally using joint venture partners
and 27 small conferences worldwide are scheduled for 2007.

Dr Robert Goldman (aged 51) is the Chairman of the American Academy of
Anti-Ageing Medicine ("A4M") and (with Dr Ronald Klatz) the Founding President
of the National Academy of Sports Medicine, USA. He has spearheaded the
development of numerous international medical organizations and corporations and
has received a number of awards including the International Olympic Committee
Tribute Diploma for the Development of Sport and Olympism and the Global Medal
for Science. He is currently Chairman of the International Medical Commission
overseeing sports medicine committees in over 176 nations. He visits an average
of 20 countries annually to promote brain research and sports medicine
programmes.

Dr Ronald Klatz (aged 51) is the developer or administrator for over 100
scientific patents and has received a number of awards in recognition. In his
capacity as A4M president, he oversees continuing medical programmes for more
than 11,500 physicians, health practitioners and scientists worldwide. He has
published a number of books in the anti-ageing field and numerous articles in
related journals. He is a respected advisor to several members of the US
Congress and devotes much of his time to research.

Dr. Goldman and Dr. Klatz will remain with the business, on substantially
similar terms and conditions as prior to the Acquisition, to continue to drive
its expansion.


Background to the anti-ageing market

Anti-ageing medicine is a fast growing clinical medical specialty and an
extension of preventive health care and is based on the early detection,
prevention, and reversal of ageing-related diseases and aesthetic procedures.
Alzheimer's disease, cataracts, prostate and skin cancer, impotence,
osteoporosis and dementia and cosmetic and transplant surgery are just some
examples of such diseases and procedures. With early detection and appropriate
intervention, many diseases can be prevented, cured, or have their downward
course reversed.

The science is multi-disciplinary covering not only established fields like
biochemistry, biology, and physiology, but extending into mind/body medicine,
sports medicine, molecular genetics, and emerging medical technologies.

In 2005, the Business Communications Company Inc. (a US research company)
estimated that turnover in the US anti-ageing medical marketplace would reach
some $49 billion in 2005 and would grow to some $72 billion by 2009, a compound
growth rate of 10% p.a.

Building on Tarsus's growing core business, which is currently trading in line
with management's expectations, the Acquisition provides Tarsus with a new
business division in a fast growing market. Tarsus now has five business
divisions covering seven market sectors. Tarsus's current sales, operating and
administrative infrastructure will strengthen MCII's market position and
together MCII's conferences and exhibitions are expected to expand rapidly, with
their main focus being in the United States. The Acquisition will increase
Tarsus's scale and will therefore provide it with a broader and more
diversified business. The Board believes that the Acquisition will be earnings
per share enhancing in the current financial year and first full year of
ownership.

Commenting on the Acquisition, Douglas Emslie, Group Managing Director of
Tarsus, said:

"We are delighted to be able to acquire MCII at this early stage of its
development. MCII has already shown its ability to grow and is in a sector of
the medical market which is itself expanding rapidly. This acquisition takes
Tarsus into a fast growing area and further broadens the number of sectors we
serve."


Vendor Placing

Part of the initial consideration for the Acquisition will be satisfied by a
Vendor Placing to raise approximately #11.0 million (#10.5 million net of
expenses in relation to the Vendor Placing and the Acquisition). KBC Peel Hunt
as agent for the Company, has conditionally placed 5,304,107 Ordinary Shares
representing 9.9% of the existing issued share capital of the Company with
institutional investors (the "Placing Shares") at a placing price of 207p per
new Ordinary Share (the "Placing Price"). The Placing Price represents a
discount of 3.6% to the closing mid-market price of 214.625p per share on 15
November 2006.

The Placing Shares will be issued credited as fully paid and will rank pari
passu in all respects with the existing Ordinary Shares, including the right to
receive any future dividends and other distributions. The Acquisition and the
Vendor Placing, which has been fully underwritten by KBC Peel Hunt, are
conditional on Admission. Attention is drawn to the detailed terms and
conditions of the Vendor Placing described in the appendix to this announcement.

Application will be made for admission of the Placing Shares to the Official
List of the United Kingdom Listing Authority and to trading on London Stock
Exchange plc's market for listed securities ("Admission") and it is expected
that dealings in the Placing Shares will commence at 8.00 a.m. on 21 November
2006.

......


Note that this is expected to be earnings enhancing in the current financial year and also earnings per share enhancing in the current financial year.

The share price is now well clear of the previous high, and just on the chart basis should continue to rise in the short term to around 260. But the business is now bigger and has prospects for even faster growth, so a further rerating may be in order.

Has anyone else even noticed?

Cheers,
Ian

[ian.g] 15/11/2006 17:49

All ticking along nicely - if today's rise is sustained then we really have a strong breakout... sad nobody here but me to enjoy it ;-)

[ian.g] 02/11/2006 12:16

Analyst/investor presentation this afternoon to cover activities in China, being published on the website tomorrow - once again TRS are managing information flow in a thorough and well-organised way.
Their Chinese operations are moving quickly, with their partnership in paper / packaging / advertising events in Shanghai, their established labelling exhibition, and last month's rebranding of the Beijing International Travel and Tourism Market to the China Outbound Travel and Tourism Market underlining the real scope of that offering, covering one of the fastest growing tourist markets in the world which promises eventually to become one of the largest.
We should see some positive press and/or brokerage response to this presentation, but mostly it's about continuing visibility of the successful implementation of their strategy for growth - TRS is gradually attracting the investor attention it deserves for the quality of its offering.